查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827207

球孢子菌病市場按藥物類別、感染類型、細菌種類、給藥途徑、分銷管道、最終用戶和患者類型分類 - 2025-2032 年全球預測

Coccidioidomycosis Market by Drug Class, Infection Type, Species, Route Of Administration, Distribution Channel, End User, Patient Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，球孢子菌病市場規模將成長至 8.1845 億美元，複合年成長率為 7.14%。

主要市場統計數據
基準年2024年 4.7123億美元
預計2025年 5.0313億美元
預測年份：2032年 8.1845億美元
複合年成長率（%） 7.14%

影響球孢子菌病臨床挑戰、診斷和治療以及策略重點的系統性因素的全面情況概述

球孢子菌病在流行地區通常被稱為山谷熱，它在臨床管理、公共衛生監測和藥物供應方面面臨多方面的挑戰。本導論分析綜合了當代臨床實踐、診斷演變和治療方法，旨在解釋為什麼臨床、監管和商業領域的相關人員必須重新調整其優先事項。由於該疾病表現形式多樣，從自限性呼吸道疾病到慢性播散性全身性疾病，及時診斷和適當的抗真菌治療至關重要，同時還需要開發更有效的診斷和治療方法方法。

抗真菌藥物研發的最新趨勢、分子和血清學診斷技術的進步，以及對免疫力缺乏患者和特定人群等弱勢群體的日益關注，正在共同重塑治療模式。同時，醫療服務提供模式的轉變和支付方動態的演變，正在影響住院和門診病患的醫療服務取得方式。本介紹將為深入評估系統性轉變、政策影響、細分領域特定影響、區域差異和實務建議奠定基礎。其目的是為領導者提供簡潔而堅實的基礎，幫助他們解讀下游分析，並在加速的臨床和商業性變革中果斷採取行動。

不斷發展的臨床診斷和治療方法與供應鏈彈性和不斷變化的流行病學相交織，重塑護理途徑和相關人員策略

由於診斷方法的進步、治療策略的改進以及整個公共衛生系統意識的提高，球孢子菌病的現狀正在發生重大變化。照護現場和實驗室分子檢測縮短了診斷時間，使臨床醫生能夠更早啟動針對性的抗真菌治療，從而改變了醫院的利用率和門診追蹤模式。同時，人口流動和氣候變遷使得人們在歷史流行區以外對該疾病的認知有所提高，迫使相關人員重新評估監測框架和臨床醫生教育計畫。

治療方案組合也在不斷發展。雖然基於對藥物動力學、藥物交互作用和患者耐受性的更深入理解，最佳化Azole藥物的選擇已成為新興趨勢，但靜脈注射製劑對於需要住院治療的重症或播散性病例仍然至關重要。這些臨床改進正在推動治療流程的修訂，並影響醫院、診所和專科中心之間的需求分配。同時，隨著製造商和經銷商適應原物料採購、監管複雜性和通路動態的變化，供應鏈韌性正成為一項策略重點。總而言之，這些變化需要對臨床開發、商業營運和公共衛生政策進行全面規劃，以將創新轉化為改善的患者療效和持續的可近性。

不斷變化的貿易政策和關稅迫使供應鏈重組和籌資策略改革，以維持抗真菌治療和臨床用品的供應

關稅政策變化的累積影響正在波及醫藥供應鏈和成本結構，顯著影響抗真菌治療藥物及相關臨床材料。進口活性藥物原料藥和成品關稅的提高，推動了供應鏈多元化的需求，促使製造商和採購團隊考慮其他籌資策略和不易受關稅波動影響的區域製造地。此類重組不僅影響定價，還影響庫存策略以及與經銷商和醫療保健提供者的合約安排。

關稅主導的成本壓力可能會加速大型醫院系統和專科中心之間的採購整合，這些機構擁有更強的談判能力和更完善的供應鏈。同時，小型診所和獨立醫療保健機構可能面臨利潤空間縮減，並且更加依賴批發商和第三方物流供應商來管理採購的複雜性。應對這些動態的製造商可能會優先考慮能夠平衡臨床效用和供應鏈可行性的劑型和給藥途徑，例如優先考慮更穩定、更易於分銷的慢性病口服劑型。總體而言，這種關稅環境凸顯了主動的供應鏈規劃、情境規劃和策略夥伴關係關係的重要性，以確保獲得基本抗真菌藥物，同時維持醫療機構的可負擔性。

細緻的臨床和商業觀點揭示了藥物類別、感染表現型、給藥途徑、分銷管道、最終用戶和患者類型的需求

細緻的細分視角闡明了治療方法選擇和護理途徑在臨床和商業性上的交叉方式。依藥物類別分析將市場分為Azole和Polyenes，Azole又細分為Fluconazole、Itraconazole、Ketoconazole和Voriconazole，每種藥物均具有獨特的療效-耐受性和藥物交互作用特徵，可為急性、慢性和播散性疾病的治療方案選擇提供參考。感染類型（慢性與播散性）決定了何時口服門診治療有利，以及何時靜脈注射對於初始住院治療至關重要。粗球孢子菌和波薩達斯球孢子菌在種級水平上的差異，有助於區分診斷和流行病學差異，這可能會影響社區監測和臨床試驗設計。

給藥途徑仍然是一個關鍵的細分軸心，靜脈注射僅用於需要快速達到治療水平的嚴重疾病，而口服製劑則有利於門診的長期管理並提高患者的依從性。將分銷管道細分為線下和線上零售，揭示了不斷變化的患者獲取模式，數位藥房和電子處方箋正在改變履約時間表和依從性支援。將最終使用者（診所、醫院、研究機構和專科中心）細分，突顯了多樣化的採購行為和臨床工作流程，進而影響產品的商業性定位和支援方式。最後，將患者類型細分為成人和小兒科，突顯了不同劑型的安全性特徵以及支持兒童使用的臨床證據的需求。結合這些細分維度，可以創建一個矩陣，為整個護理過程中的產品開發優先順序、商業性獲取策略和臨床教育工作提供資訊。

地方性臨床能力和法律規範的地區差異導致全部區域醫療准入途徑和策略重點不同

區域動態對不同地區疾病發生率相關的臨床實務和市場行為有顯著影響。在美洲，疫情熱點地區集中了臨床專業知識、診斷基礎設施和專業的醫療途徑，有助於快速識別病例並啟動治療。同時，這些地區內部和跨地區的人口流動正在傳播臨床意識，並推動對可擴展診斷的需求。中東和非洲地區呈現出一種異質性格局，零星的輸入性病例與特定醫療機構不斷增強的診斷能力並存，這促使開展有針對性的臨床醫生教育和跨境監測合作，以確保及時識別和管理。

儘管亞太地區對抗真菌藥物的認知度正在提高，抗真菌藥物的可及性仍然不均衡，醫院基礎設施和分銷網路的差異影響了都市區地區的治療實踐。區域法律規範和報銷環境進一步影響了新診斷和治療方法的採用，因此需要製定兼顧當地政策、臨床規範和經銷夥伴關係的打入市場策略。在各個地區，協調一致的實驗室能力建設和第一線臨床醫生的繼續醫學教育對於改善治療結果、減少診斷和治療啟動的延誤仍然至關重要。

競爭策略強調證據生成、最佳化、經銷夥伴和診斷整合，以向臨床醫生和醫療保健提供者提案差異化的價值主張

縱觀競爭格局，各公司和機構正在採用差異化策略來滿足臨床需求，並鞏固其在抗真菌治療和診斷領域的地位。一些公司專注於透過研究者主導的臨床實驗和真實世界數據收集來增強臨床證據，以證明藥物在慢性和播散性疾病中的相對療效和長期安全性。其他機構則優先考慮配方創新、最佳化生物有效性，並制定患者友善的給藥方案，以支持門診患者的依從性。隨著利益相關人員尋求在監管和關稅壓力下簡化分銷流程並確保供應的連續性，製造商、合約研究組織和專業藥房之間的策略聯盟日益普遍。

同時，診斷公司正在投資更靈敏的檢測方法和連接複用平台，以快速區分病原體，從而支持標靶治療選擇。醫院、診所和研究機構等機構終端使用者正在加大對臨床醫生培訓和抗菌藥物管理計畫的投資，以確保抗真菌藥物的選擇符合最佳實踐指南。總而言之，這些企業級措施反映出企業正轉向整合產品服務，將治療與診斷和教育支援相結合，為醫生付款人和採購團隊提供差異化的價值提案。

領導者應採取切實可行的策略行動，協調開發、分銷和臨床教育工作，同時加強供應鏈和市場進入途徑

產業領導者應採取一系列切實可行的措施，充分利用臨床進展並降低營運風險。首先，應將臨床開發重點與未滿足的需求結合，投資進行比較研究，明確Fluconazole、Itraconazole、Ketoconazole和Voriconazole在不同患者亞群中的相對優勢，並支持兒科製劑改進研究。其次，應加強供應鏈韌性，實現原料藥來源多元化，並探索區域製造夥伴關係，以降低貿易中斷和關稅相關成本衝擊帶來的風險。

第三，制定全面的打入市場策略，整合線下和線上零售管道，並認知到電子處方和數位藥房服務將如何重塑患者的履約和依從性。第四，積極與終端使用者診所、醫院、研究機構和專科中心合作，提供臨床教育和管理資源，以促進在慢性和播散性病例中合理使用抗真菌藥物。最後，尋求與診斷開發人員的合作機會，共同開發捆綁式解決方案，簡化從診斷到治療的流程，並透過展示臨床和營運價值來支持與付款方的討論。這些建議優先考慮靈活性和整合性，以確保持續的可近性和改善的患者治療效果，同時應對政策和市場的複雜性。

嚴格的多源研究框架，整合文獻綜合、專家訪談和資料三角測量，檢驗臨床操作和政策見解

本分析所依據的研究將多源情報與方法檢驗相結合，以確保研究結果可靠且可操作。二次研究涵蓋同行評審文獻、臨床指南、監管出版物和公共衛生監測報告，旨在建立涵蓋疾病流行病學、診斷性能和治療方法的全面依證。此外，我們也進行了有針對性的一手研究，包括對臨床專家、醫院藥劑師、供應鏈經理和經銷商進行結構化訪談，以增強研究的有效性，並檢驗新興主題。

數據合成運用三角測量技術，將臨床證據、採購慣例和當地政策背景的研究結果進行整合。調查方法和數據來源優先考慮引文透明度和對證據品質的嚴格評估，將觀察性數據與真實世界數據相聯繫，同時強調高品質的隨機試驗和檢驗的診斷性能測試。對於存在差距的地方，專家諮詢提供了解釋指導，以確保結論在臨床上有效且在操作上適當。由此產生的分析框架可支援產生可重複的見解，並可適用於持續監測和定期報告更新。

臨床實務與政策要求的結合凸顯了採取實證協作策略以改善獲取結果和供應彈性的必要性

總而言之，圍繞球孢子菌病的臨床、商業性和政策格局正在不斷演變，需要採取協調一致的應對措施，將診斷和治療供應鏈管理與臨床醫生的參與結合起來。分子和血清學檢測的進步，加上Azole和Polyenes在慢性和播散性疾病中更先進的治療應用，如果透過教育和管理轉化為實踐，將為改善患者預後創造機會。同時，貿易政策和關稅的發展凸顯了積極主動的供應鏈規劃以及策略性地分配製造和採購資源以維持醫療服務的連續性的重要性。

製造商、醫療保健提供者和付款人之間的策略合作對於將科學和營運方面的進步轉化為可近性和療效的實際改善至關重要。持續投資於證據生成，加上本地客製化的可及性策略和綜合診斷與治療解決方案，將使相關人員能夠應對不確定性，並為受影響的患者提供更好的護理。本綜述為明智的決策奠定了基礎，並強調了在不斷變化的流行病學和政策動態環境中採取靈活、循證驅動方法的必要性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 氣候變遷和人口流動導致球孢子菌病發生率增加
  • 新型抗真菌藥物在山谷熱後期臨床試驗的進展
  • 整合快速POC診斷平台，提升早期檢測能力
  • 隨著私人和公共資金的增加，疫苗開發平臺不斷推進
  • 影響疾病管理報銷和覆蓋範圍的地方政府醫療保健政策的修訂
  • 擴大遠端醫療服務，支持對球孢子菌病患者的遠端監控
  • 流行地區對包含球孢子菌病目標的多重呼吸道檢測板的需求不斷增加
  • 利用人工智慧驅動的影像分析來區分肺結節和惡性腫瘤
  • 人們越來越有興趣教育基層醫療提供者有關山谷熱的鑑別診斷，以減少因誤診而造成的延誤。

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 球孢子菌病市場（依藥物類別）

  • Azole
    • Fluconazole
    • Itraconazole
    • Ketoconazole
    • Voriconazole
  • Polyenes

9. 球孢子菌病市場（依感染類型）

  • 慢性的
  • 傳播

10. 球孢子菌病市場（依種類）

  • 粗球孢子菌
  • 波薩達斯球孢子菌

11. 球孢子菌病市場（依給藥途徑）

  • 靜脈
  • 口服

12. 球孢子菌病市場（依分銷管道）

  • 線下零售
  • 網路零售

13. 球孢子菌病市場（依最終用戶）

  • 診所
  • 醫院
  • 研究所
  • 專業中心

14. 球孢子菌病市場（依患者類型）

  • 成人
  • 孩子們

15. 球孢子菌病市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

16. 球孢子菌病市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

17. 球孢子菌病市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Quest Diagnostics Incorporated
    • Meridian Bioscience, Inc.
    • Laboratory Corporation of America Holdings
    • IMMY
    • Mayne Pharma Group Limited
    • Meridian Bioscience, Inc.
    • Mycovia Pharmaceuticals, Inc.
    • Scynexis, Inc.
    • Pfizer Inc.
    • Gilead Sciences, Inc.
    • Merck & Co., Inc.
    • CELLTRION INC.
    • Shionogi & Co., Ltd.
Product Code: MRR-81515600A08C

The Coccidioidomycosis Market is projected to grow by USD 818.45 million at a CAGR of 7.14% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 471.23 million
Estimated Year [2025] USD 503.13 million
Forecast Year [2032] USD 818.45 million
CAGR (%) 7.14%

Comprehensive contextual overview of coccidioidomycosis clinical challenges and systemic factors reshaping diagnosis treatment delivery and strategic priorities

Coccidioidomycosis, often referred to as valley fever in endemic regions, presents a multifaceted challenge spanning clinical management, public health surveillance, and pharmaceutical supply. This introductory analysis synthesizes contemporary clinical practice, diagnostic evolution, and therapeutic approaches to frame why stakeholders across clinical, regulatory, and commercial spheres must recalibrate priorities. The disease's variable presentation, ranging from self-limited respiratory illness to chronic and disseminated systemic disease, places a premium on timely diagnosis and appropriate antifungal therapy, while also driving demand for more effective diagnostics and treatment pathways.

Recent advances in antifungal development, improvements in molecular and serologic diagnostics, and heightened focus on vulnerable populations such as immunocompromised patients and certain demographic cohorts have collectively reshaped care paradigms. Simultaneously, shifting healthcare delivery models and evolving payer dynamics influence how treatments are accessed across inpatient and outpatient settings. This introduction sets the stage for a deeper assessment of systemic shifts, policy impacts, segmentation-specific implications, regional nuances, and practical recommendations that follow. The goal is to equip leaders with a concise yet robust foundation to interpret downstream analyses and to act decisively in an environment of accelerating clinical and commercial change.

Evolving clinical diagnostics and therapeutic modalities intersect with supply chain resilience and shifting epidemiology to reshape care pathways and stakeholder strategies

The landscape for coccidioidomycosis is undergoing transformative shifts driven by advances in diagnostics, therapeutic strategy refinement, and expanded awareness across public health systems. Point-of-care and laboratory-based molecular assays are shortening time to diagnosis, enabling clinicians to initiate targeted antifungal therapy earlier, which in turn changes patterns of hospital utilization and outpatient follow-up. Concurrently, growing recognition of the disease outside historically endemic zones, influenced by population mobility and climate-related shifts, has compelled stakeholders to reassess surveillance frameworks and clinician education programs.

Therapeutic portfolios are also evolving. There is a clear trend toward optimizing azole therapy selection based on better understanding of pharmacokinetics, drug-drug interactions, and patient tolerance, while intravenous formulations remain essential for severe and disseminated cases that require hospital-based care. These clinical refinements are prompting revisions in treatment algorithms and influencing the distribution of demand across hospitals, clinics, and specialty centers. In parallel, supply chain resilience is becoming a strategic priority as manufacturers and distributors adapt to changes in raw material sourcing, regulatory complexity, and channel dynamics. Taken together, these shifts necessitate integrated planning across clinical development, commercial operations, and public health policy to translate innovation into improved patient outcomes and sustained access.

Shifts in trade policy and tariff measures are compelling supply chain realignment and procurement strategy reform to preserve access to antifungal treatments and clinical supplies

The cumulative impact of tariff policy developments has rippled through pharmaceutical supply chains and cost structures with material implications for antifungal therapies and related clinical supplies. Increased duties on imported active pharmaceutical ingredients and finished formulations have heightened the need for supply chain diversification, prompting manufacturers and procurement teams to evaluate alternative sourcing strategies and to consider regional manufacturing hubs that reduce exposure to tariff volatility. This realignment affects not only pricing considerations but also inventory strategies and contractual arrangements with distributors and healthcare providers.

Tariff-driven cost pressures can accelerate the consolidation of purchasing among larger hospital systems and specialty centers that possess greater negotiating power and supply chain sophistication. At the same time, smaller clinics and independent providers may face tighter margins and increased reliance on wholesalers and third-party logistics providers to manage procurement complexity. Manufacturers responding to these dynamics may prioritize product formulations and routes of administration that balance clinical utility with supply chain feasibility, such as favoring oral agents for chronic management where stability and distribution are more straightforward. Overall, the tariff environment underscores the importance of proactive supply chain mapping, scenario planning, and strategic partnerships to safeguard access to essential antifungal therapies while maintaining affordability across care settings.

Segmented clinical and commercial perspectives reveal differentiated needs across drug classes infection phenotypes routes of administration distribution channels end users and patient types

A nuanced segmentation lens reveals how therapeutic choices and care pathways intersect with distinct clinical and commercial imperatives. When analyzed by drug class, the market divides between azoles and polyenes, with azoles further differentiated into fluconazole, itraconazole, ketoconazole, and voriconazole, each offering a distinct efficacy tolerability and drug interaction profile that informs regimen selection for acute chronic and disseminated presentations. Differentiation by infection type-chronic versus disseminated-clarifies where outpatient oral therapies predominate versus where intravenous interventions are essential for initial management in hospital settings. Species-level considerations between Coccidioides immitis and Coccidioides posadasii contribute to subtle diagnostic and epidemiologic distinctions that can influence regional surveillance and clinical trial design.

Route of administration remains a pivotal segmentation axis, with intravenous delivery reserved for severe disease requiring rapid therapeutic levels and oral formulations facilitating long-term management and improved patient adherence in ambulatory care. Distribution channel segmentation into offline retail and online retail highlights evolving patient access patterns, with digital pharmacies and e-prescribing altering fulfillment timelines and adherence support. End user segmentation across clinics hospitals research institutes and specialty centers underscores diverse procurement behaviors and clinical workflows, affecting how products are positioned and supported commercially. Finally, patient type segmentation into adults and pediatrics emphasizes distinct dosing formulations safety profiles and the need for tailored clinical evidence to support pediatric use. Together these segmentation dimensions create a matrix that informs product development priorities, commercial access strategies, and clinical education efforts across the care continuum.

Regional variations in endemicity clinical capabilities and regulatory frameworks drive distinct access pathways and strategic priorities across the Americas EMEA and Asia Pacific

Regional dynamics exert a profound influence on disease incidence clinical practice and market behavior across distinct geographies. In the Americas, endemic hotspots concentrate clinical expertise, diagnostic infrastructure, and specialty care pathways that shape rapid case identification and treatment initiation, while population mobility within and beyond these regions spreads clinical awareness and drives demand for scalable diagnostics. Europe Middle East & Africa present heterogenous landscapes where sporadic imported cases coexist with growing diagnostic capacity in select centers, prompting targeted clinician education and cross-border surveillance collaborations to ensure timely recognition and management.

Asia-Pacific shows a mix of emerging awareness and variable access to antifungal therapies, with disparities in hospital infrastructure and distribution networks influencing how care is delivered in urban centers versus peripheral regions. Regional regulatory frameworks and reimbursement environments further modulate adoption of newer diagnostics and therapeutics, necessitating tailored market entry strategies that account for local policy, clinical practice norms, and distribution partnerships. Across all regions, coordinated capacity-building for laboratories and continuing medical education for frontline clinicians remains critical to improving outcomes and reducing delays in diagnosis and treatment initiation.

Competitive strategies emphasize evidence generation formulation optimization distribution partnerships and diagnostics integration to create differentiated value propositions for clinicians and providers

Across the competitive landscape, companies and institutions are adopting differentiated strategies to address clinical needs and to strengthen their position in antifungal therapeutics and diagnostics. Some organizations concentrate on enhancing clinical evidence through investigator-initiated studies and real-world data collection to demonstrate comparative effectiveness and long-term safety in chronic and disseminated disease. Others prioritize formulation innovation, optimizing oral bioavailability or creating patient-friendly dosing regimens that support adherence in outpatient settings. Strategic partnerships between manufacturers, contract development organizations, and specialty pharmacies are increasingly common as stakeholders seek to streamline distribution and to ensure continuity of supply in the face of regulatory and tariff pressures.

In parallel, diagnostic firms are investing in higher-sensitivity assays and multiplex platforms that enable faster differentiation of etiologic agents, thereby supporting targeted therapy selection. Institutional end users such as hospitals, clinics, and research institutes are escalating investments in clinician training and in antimicrobial stewardship programs that align antifungal selection with best practice guidelines. Collectively, these company-level moves reflect a shift toward integrated offerings that combine therapeutic agents with diagnostic and educational support to create differentiated value propositions for physicians payers and procurement teams.

Practical strategic actions for leaders to align development distribution and clinical education efforts while strengthening supply chains and market access pathways

Industry leaders should adopt a pragmatic set of actions to capitalize on clinical advances and to mitigate operational risks. First, align clinical development priorities with unmet needs by investing in comparative studies that clarify the relative advantages of fluconazole itraconazole ketoconazole and voriconazole across patient subgroups, while also supporting research into improved formulations for pediatric use. Second, strengthen supply chain resilience by diversifying sourcing for active pharmaceutical ingredients and by exploring regional manufacturing partnerships that reduce exposure to trade disruptions and tariff-related cost shocks.

Third, develop comprehensive market access strategies that incorporate both offline retail and online retail channels, recognizing how e-prescribing and digital pharmacy services reshape patient fulfillment and adherence. Fourth, engage proactively with end users-clinics hospitals research institutes and specialty centers-to deliver tailored clinical education and stewardship resources that facilitate appropriate antifungal use across chronic and disseminated cases. Finally, pursue collaborative opportunities with diagnostic developers to co-develop bundled solutions that streamline diagnosis-to-treatment pathways and support payer discussions by demonstrating clinical and operational value. These recommendations prioritize agility and integration to ensure sustained access and improved patient outcomes while navigating policy and market complexity.

Rigorous multi-source research framework integrating literature synthesis expert interviews and data triangulation to validate clinical operational and policy insights

The research underpinning this analysis combined multi-source intelligence and methodical validation to ensure robust, actionable findings. Secondary research encompassed peer-reviewed literature clinical guidelines regulatory publications and public health surveillance reports to construct a comprehensive evidence base on disease epidemiology diagnostic performance and therapeutic approaches. This literature-driven foundation was augmented by targeted primary research consisting of structured interviews with clinical experts, hospital pharmacists, supply chain managers, and distributors to capture real-world operational insights and to validate emergent themes.

Data synthesis employed triangulation techniques to reconcile findings across clinical evidence, procurement practices, and regional policy contexts. The methodology prioritized transparency in source attribution and critical assessment of evidence quality, placing greater weight on high-quality randomized trials and validated diagnostic performance studies while contextualizing observational and real-world data. Where gaps existed, expert elicitation provided interpretive guidance to ensure conclusions remained clinically plausible and operationally relevant. The resulting analytical framework supports reproducible insight generation and can be adapted for ongoing surveillance and periodic report updates.

Synthesis of clinical operational and policy imperatives highlighting the need for coordinated evidence aligned strategies to improve access outcomes and supply resilience

In conclusion, the evolving clinical, commercial, and policy landscape around coccidioidomycosis requires coordinated responses that bridge diagnostics therapeutics supply chain management and clinician engagement. Advances in molecular and serologic testing, coupled with more refined therapeutic use of azoles and polyenes across chronic and disseminated presentations, create opportunities to improve patient outcomes when translated into practice through education and stewardship. At the same time, trade policy and tariff developments emphasize the importance of proactive supply chain planning and the strategic allocation of manufacturing and procurement resources to maintain continuity of care.

Strategic alignment among manufacturers distributors providers and payers will be essential to converting scientific and operational progress into tangible improvements in access and outcomes. Continued investment in evidence generation, coupled with regionally tailored access strategies and integrated diagnostic-treatment solutions, will enable stakeholders to navigate uncertainty and to deliver better care for affected patients. This synthesis offers a basis for informed decision-making and underscores the necessity of agile, evidence-aligned approaches in an environment of shifting epidemiology and policy dynamics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing incidence of coccidioidomycosis driven by climate change and population migration
  • 5.2. Advancement of novel antifungal agents in late stage clinical trials for valley fever
  • 5.3. Integration of rapid point of care diagnostic platforms to improve early detection
  • 5.4. Progress in vaccine development pipelines amid increasing private and public funding
  • 5.5. Municipal healthcare policy revisions affecting disease management reimbursement and coverage
  • 5.6. Expansion of telemedicine services to support remote monitoring of coccidioidomycosis patients
  • 5.7. Increasing demand for multiplex respiratory panels incorporating coccidioidomycosis targets in endemic settings
  • 5.8. Adoption of artificial intelligence driven imaging analysis to differentiate coccidioidomycosis lung nodules from malignancy
  • 5.9. Rising interest in educating primary care providers on differential diagnosis of valley fever to reduce misdiagnosis delays

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Coccidioidomycosis Market, by Drug Class

  • 8.1. Azoles
    • 8.1.1. Fluconazole
    • 8.1.2. Itraconazole
    • 8.1.3. Ketoconazole
    • 8.1.4. Voriconazole
  • 8.2. Polyenes

9. Coccidioidomycosis Market, by Infection Type

  • 9.1. Chronic
  • 9.2. Disseminated

10. Coccidioidomycosis Market, by Species

  • 10.1. Coccidioides Immitis
  • 10.2. Coccidioides Posadasii

11. Coccidioidomycosis Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral

12. Coccidioidomycosis Market, by Distribution Channel

  • 12.1. Offline Retail
  • 12.2. Online Retail

13. Coccidioidomycosis Market, by End User

  • 13.1. Clinics
  • 13.2. Hospitals
  • 13.3. Research Institutes
  • 13.4. Specialty Centers

14. Coccidioidomycosis Market, by Patient Type

  • 14.1. Adults
  • 14.2. Pediatrics

15. Coccidioidomycosis Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Coccidioidomycosis Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Coccidioidomycosis Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Quest Diagnostics Incorporated
    • 18.3.2. Meridian Bioscience, Inc.
    • 18.3.3. Laboratory Corporation of America Holdings
    • 18.3.4. IMMY
    • 18.3.5. Mayne Pharma Group Limited
    • 18.3.6. Meridian Bioscience, Inc.
    • 18.3.7. Mycovia Pharmaceuticals, Inc.
    • 18.3.8. Scynexis, Inc.
    • 18.3.9. Pfizer Inc.
    • 18.3.10. Gilead Sciences, Inc.
    • 18.3.11. Merck & Co., Inc.
    • 18.3.12. CELLTRION INC.
    • 18.3.13. Shionogi & Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. COCCIDIOIDOMYCOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. COCCIDIOIDOMYCOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COCCIDIOIDOMYCOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY KETOCONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY VORICONAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CHRONIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISSEMINATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES IMMITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY COCCIDIOIDES POSADASII, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY OFFLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL COCCIDIOIDOMYCOSIS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 308. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 309. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 310. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 311. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 312. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 313. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 316. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 317. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 319. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. GCC COCCIDIOIDOMYCOSIS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY AZOLES, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY INFECTION TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY SPECIES, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPEAN UNION COCCIDIOIDOMYCOSIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION COCCIDIOIDOMYCOSI